Overview

Long-Term Treatment of Collagenous Colitis With Budesonide

Status:
Unknown status
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to examine the effect of budesonide treatment on collagenous colitis. All patients is treated for 6 weeks with budesonide and thereafter randomised to 24 weeks treatment with placebo or continued budesonide. The end poit is effect on clinical symptoms (number of daily stools)
Phase:
Phase 3
Details
Lead Sponsor:
Bonderup, Ole K., M.D.
Collaborator:
AstraZeneca
Treatments:
Budesonide